Bacterial mercury resistance from atoms to ecosystems.

T. Barkay,Susan M. Miller,A. Summers

DOI: https://doi.org/10.1016/S0168-6445(03)00046-9

2003-06-01

FEMS Microbiology Reviews

Abstract:

What problem does this paper attempt to address?

Alisporivir, a cyclosporin derivative that selectively inhibits cyclophilin, for the treatment of HCV infection.

Koichi Watashi

2010-02-01

Abstract:HCV infection is the primary cause of chronic liver disease. Host cell cyclophilins (Cyps) are essential for efficient HCV replication in hepatocytes, and thus Cyps are regarded as a new target for anti-HCV therapy. Alisporivir (Debio-025), a non-immunosuppressive cyclosporine A derivative that selectively inhibits Cyps, is being developed by Debiopharm SA for the potential oral treatment of HCV infection. In the HCV subgenomic replicon system, alisporivir suppressed viral replication more potently than cyclosporine A. A phase II clinical trial demonstrated that treatment with alisporivir alone or combined with PEGylated IFNalpha2a reduced the viral load in patients with chronic HCV infection. The drug was also generally well tolerated. In contrast, a phase I trial of alisporivir monotherapy in patients with HIV-1 infection suggested that the drug has a limited effect on HIV-1 viral load. Alisporivir was also investigated in animal models of muscular dystrophy, acute myocardial infarction and brain disorders. At the time of publication, two phase II trials, evaluating alisporivir alone and in combination with PEGylated IFNalpha2a or with PEGylated IFNalpha2a and ribavirin, were ongoing in treatment-naïve patients with HCV-1 infection and in patients with chronic HCV-1 infection who were prior non-responders to PEGylated IFNalpha or ribavirin.
HER2-Directed Therapy in Advanced Gastric and Gastroesophageal Adenocarcinoma: Triumphs and Troubles

Brian C Grieb,Rajiv Agarwal

DOI: https://doi.org/10.1007/s11864-021-00884-7

2021-08-23

Abstract:Gastric and gastroesophageal junction (GEJ) cancers represent the third leading cause of malignancy-associated death worldwide. Approximately 15-20% of these adenocarcinomas overexpress the human epidermal growth factor receptor 2 (HER2), a pro-proliferative receptor tyrosine kinase that has been therapeutically exploited in other disease contexts. The landmark ToGA trial demonstrated that trastuzumab, an anti-HER2 antibody, could improve overall survival for patients with HER2 overexpressing advanced gastric and GEJ adenocarcinomas. In the ensuing decade, great effort has been made to refine and expand this therapeutic strategy through a variety of avenues including optimization of chemotherapy backbones, identifying potential synergy with immune checkpoint inhibition, deployment of alternative HER2-targeted antibodies, use of small molecule inhibitors, and development of HER2-directed antibody drug conjugates. While the results of these efforts have had variable success, they have led to a greater understanding of the mechanisms of both primary and acquired resistance to HER2-directed therapies, laying the groundwork for future investigations. Recently, KEYNOTE-811 and DESTINY-Gastric01 have led to the FDA approvals of pembrolizumab in combination with trastuzumab and chemotherapy in the 1st-line advanced setting and trastuzumab deruxtecan (fam-trastuzumab deruxtecan-nxki) in the 2nd-line setting, respectively. Herein, we review these significant works as well as discuss the ongoing investigations they have inspired, which aim to find and utilize additional means for targeting HER2 in gastric and GEJ cancers.
Immune checkpoint inhibitors combined with HER-2 targeted therapy in HER-2 positive gastroesophageal cancer

Adilai Aisa,Shanshan Weng,Xinyu Li,Ding Zhang,Ying Yuan

DOI: https://doi.org/10.1016/j.critrevonc.2022.103864

IF: 6.625

2022-01-01

Critical Reviews in Oncology/Hematology

Abstract:GEC is one of the most common cancers and has become a significant health burden worldwide. HER-2 is a protooncogene, amplified or overexpressed in different tumors, and associated with a worse prognosis. Trastuzumab plus chemotherapy is the current standard treatment for advanced HER-2 positive GEC. However, it still does not benefit well all patients. HER-2 targeted therapy can up-regulate the expression of PD-1, CTL-4, and TAMs in the tumor microenvironment, strengthen the ADCC process, and enhance the efficacy of immunotherapy. While immune checkpoint inhibitors could reduce drug resistance to anti-HER-2 drugs. Moreover, immunotherapy combined with HER-2 targeted therapy in HER-2 positive GEC has shown perceptible efficacy and acceptable side effects in clinical trials and is regarded as a new therapeutic strategy for GEC. However, there remain significant challenges and requires more research to improve the survival benefit of this therapeutic approach.
What Happened to Detail and Discussion?

B. Dixon

DOI: https://doi.org/10.1038/NBT1285-1046

1985-12-01

Bio/Technology

Abstract:
Topical antineoplastic agents in the treatment of mucocutaneous diseases.

A. Grossberg,A. Gaspari

DOI: https://doi.org/10.1159/000321056

Current Problems in Dermatology

Abstract:Topical antineoplastic agents have a well-established role in the treatment of several dermatological conditions. Their use in the treatment of mucosal skin disease also has gained increasing recognition. Topical 5-fluorouracil (5-FU), an antimetabolite, and imiquimod, an immunomodulatory agent with antitumor properties, are the two principal topical antineoplastic agents used in the treatment of mucocutaneous diseases. Although the vast majority of their mucosal uses are currently not approved by the Federal Drug Administration, there are numerous case series, open-label studies and randomized controlled trials supporting their uses in the treatment of mucocutaneous diseases. Both topical 5-FU and imiquimod have been successfully utilized in the treatment of a wide range of mucosal diseases, including actinic cheilitis, Bowen's disease of the anal and vulvar mucosa, and genital and perianal condyloma. Reports of their uses in the treatment of mucocutaneous diseases indicate that these agents can be safely administered, though adverse effects such as local inflammation may be augmented when these agents are applied to mucosal surfaces. Additionally, locally acting intralesional chemotherapeutic agents, such as bleomycin and interferon, have well-defined applications in the treatment of mucosal skin diseases such as condyloma acuminata. As further studies are conducted, these topical and intralesional neoplastic agents, in addition to emerging agents that are in various stages of development, such as Toll-like receptor 9 agonists and ingenol mebutate, may play an increasingly important role in the future treatment of mucocutaneous diseases.
From rings to crescents: a novel fabrication technique uncovers the transition details.

V. Bochenkov,Duncan S Sutherland

DOI: https://doi.org/10.1021/nl304675w

2013-03-01

Abstract:A novel fabrication route is reported for the generation of substrate-supported symmetric and asymmetric metal nanostructures. We combine a colloidal template and angled evaporation to deposit in situ mask materials for subsequent lithographic pattern transfer. The technique is demonstrated for the fabrication of concentric and nonconcentric gold rings and crescents. Optical properties of localized plasmon resonances in such structures are studied by UV-vis-NIR spectroscopy and finite-difference time domain simulations during the transition from rings to crescents revealing the development of strong quadrupolar modes.
Th1 and Th2 cells.

C. Dong,R. Flavell

DOI: https://doi.org/10.1097/00062752-200101000-00009

Current Opinion in Hematology

Abstract:After activation, CD4 helper T (Th) cells differentiate into Th1or Th2 effector subsets. These two types of cells produce distinct profiles of cytokines and regulate different immune responses. This review summarizes recent progress on different features of co-stimulatory regulation and chemokine-mediated homing of Th1 and Th2 cells. Transcription factors and signaling pathways that are selectively expressed or activated in Th1 and Th2 cells to regulate cytokine gene expression are discussed.
Room-temperature triggered single photon emission from a III-nitride site-controlled nanowire quantum dot.

M. Holmes,Kihyun Choi,S. Kako,M. Arita,Y. Arakawa

DOI: https://doi.org/10.1021/nl404400d

2014-01-14

Abstract:We demonstrate triggered single photon emission at room temperature from a site-controlled III-nitride quantum dot embedded in a nanowire. Moreover, we reveal a remarkable temperature insensitivity of the single photon statistics, and a g((2))[0] value at 300 K of just 0.13. The combination of using high-quality, small, site-controlled quantum dots with a wide-bandgap material system is crucial for providing both sufficient exciton confinement and an emission spectrum with minimal contamination in order to enable room temperature operation. Arrays of such single photon emitters will be useful for room-temperature quantum information processing applications such as on-chip quantum communication.
HER2-Positive Gastric Cancer and Antibody Treatment: State of the Art and Future Developments

Magdalena K. Scheck,Ralf D. Hofheinz,Sylvie Lorenzen

DOI: https://doi.org/10.3390/cancers16071336

2024-03-30

Cancers

Abstract:Despite a decreasing incidence in Western countries, gastric cancer is among the most common cancer subtypes globally and is associated with one of the highest tumor-related mortality rates. Biomarkers play an increasing role in the treatment against gastric cancer. HER2 was one of the first biomarkers that found its way into clinical practice. Since the ToGA trial, trastuzumab has been part of first-line palliative chemotherapy in metastatic or unresectable gastric cancer. HER2-targeting agents, such as the tyrosine kinase inhibitor lapatinib, the antibody drug conjugate (ADC) trastuzumab-emtansine or dual HER2 inhibition (pertuzumab and trastuzumab), have been investigated in the second-line setting but led to negative study results. More recently, the ADC trastuzumab-deruxtecan was authorized after the failure of trastuzumab-based treatment. However, further improvements in HER2-directed therapy are required as resistance mechanisms and HER2 heterogeneity limit the existing treatment options. This review aims to give an overview of the current standard-of-care HER2-directed therapy in gastric cancer, as well as its challenges and future developments.

oncology
KEYNOTE-811: Potential to revise first-line therapy for metastatic human epidermal growth factor receptor 2-positive gastric cancer

Yuwei Ding,Ying Yuan,Shanshan Weng

DOI: https://doi.org/10.1002/mco2.545

2024-01-01

MedComm

Abstract:The first-line therapy pattern transition of metastatic HER2-positive gastric cancer is shifting. The KEYNOTE-811 study demonstrated that the addition of immunotherapy to the standard treatment of HER2-targeted therapy and chemotherapy showed good results in terms of PFS, especially in subgroup patients with PD-L1 CPS >= 1. In the future, the first-line therapy pattern of metastatic HER2-positive gastric cancer will be radically changed based on ongoing randomized controlled clinical trials. The first-line therapy pattern transition of metastatic human epidermal growth factor receptor 2 (HER2)-positive gastric cancer (GC) is shifting. The KEYNOTE-811 study demonstrated that the addition of immunotherapy to the standard treatment of HER2-targeted therapy and chemotherapy showed good results in terms of progression-free survival, especially in subgroup patients with programmed cell death ligand 1 combined positive score >= 1. In the future, the first-line therapy pattern of metastatic HER2-positive GC will be radically changed based on ongoing randomized controlled clinical trials. image
Fe-salphen complexes from intracellular pH-triggered degradation of Fe3O4@Salphen-InIII CPPs for selectively killing cancer cells.

Shuai Xu,Jing Liu,D. Li,Liming Wang,Jia Guo,Changchun Wang,Chunying Chen

DOI: https://doi.org/10.1016/j.biomaterials.2013.10.081

IF: 14

2014-02-01

Biomaterials

Abstract:
Targeting HER2-positive breast cancer: advances and future directions

Sandra M. Swain,Mythili Shastry,Erika Hamilton

DOI: https://doi.org/10.1038/s41573-022-00579-0

IF: 112.288

2022-11-08

Nature Reviews Drug Discovery

Abstract:The long-sought discovery of HER2 as an actionable and highly sensitive therapeutic target was a major breakthrough for the treatment of highly aggressive HER2-positive breast cancer, leading to approval of the first HER2-targeted drug — the monoclonal antibody trastuzumab — almost 25 years ago. Since then, progress has been swift and the impressive clinical activity across multiple trials with monoclonal antibodies, tyrosine kinase inhibitors and antibody–drug conjugates that target HER2 has spawned extensive efforts to develop newer platforms and more targeted therapies. This Review discusses the current standards of care for HER2-positive breast cancer, mechanisms of resistance to HER2-targeted therapy and new therapeutic approaches and agents, including strategies to harness the immune system.

pharmacology & pharmacy,biotechnology & applied microbiology
HER2 + advanced gastric cancer: Current state and opportunities (Review)

Hui-Hui Hu,Sai-Qi Wang,Huichen Zhao,Zhe-Sheng Chen,Xiaojing Shi,Xiao-Bing Chen

DOI: https://doi.org/10.3892/ijo.2024.5624

2024-02-19

International Journal of Oncology

Abstract:Human epidermal growth factor receptor 2 (HER2)+ gastric cancer (GC) is a distinct subtype of GC, accounting for 10‑20% of all cases of GC. Although the development of the anti‑HER2 monoclonal antibody trastuzumab has markedly improved response rates and prognosis of patients with HER2+ advanced GC (AGC), drug resistance remains a considerable challenge. Therefore, dynamic monitoring of HER2 expression levels can facilitate the identification of patients who may benefit from targeted therapy. Besides trastuzumab, DS‑8201 and RC48 have been applied in the treatment of HER2+ AGC, and several novel anti‑HER2 therapies are undergoing preclinical/clinical trials. At present, combination immunotherapy with anti‑HER2 agents is used as the first‑line treatment of this disease subtype. New promising approaches such as chimeric antigen receptor T‑cell immunotherapy and cancer vaccines are also being investigated for their potential to improve clinical outcomes. The current review provides new insights that will guide the future application of anti‑HER2 therapy by summarizing research progress on targeted therapy drugs for HER2+ AGC and combination treatments.

oncology
[A simple method for the synthesis of phosphatidylcholine with the fatty acid substituted in the 2-position].

G. Schulze,K. Jung,D. Kunze,E. Egger

Abstract:The preparation of PC with the 14C-fatty acids palmitic, stearic, oleic and linoleic acid at OH-group in position 2 is described. The starting material is egg yolk lecithin. By the attack of snake venom phospholiphase lyso-PC is produced which is reacylated by the appropriate fatty acid anhydride. In comparison with the methods published up to now this preparation has the advantage of higher yields and greater simplicity. By means of in vivo synthesis it is impossible to get PC species with only one fatty acid in a defined position. Working with radioactive fatty acids the specific radioactivity can be adapted to the requirements. The procedure can be made on a semi-technical scale.
HER2-targeted Advanced Metastatic Gastric/gastroesophageal Junction Adenocarcinoma: Treatment Landscape and Future Perspectives.

Weiling Li,Xiaoling Zhang,Yunyi Du,Ying Zhang,Jing Lu,Wenqing Hu,Jun Zhao

DOI: https://doi.org/10.1186/s40364-022-00416-x

2022-01-01

Biomarker Research

Abstract:Recently, the global incidence of gastric/gastroesophageal junction (G/GEJ) cancer has remained high. China is also a large country with a high gastric cancer (GC) incidence rate, where the cases of GC account for 40% of all cases worldwide. More than 90% of GEJ cancers are the adenocarcinoma pathological type. Patients with early-stage G/GEJ adenocarcinoma may have a better prognosis after surgery. In contrast, patients with advanced metastatic G/GEJ adenocarcinoma usually choose comprehensive treatment based on systemic pharmacotherapy, but the subsequent long-term survival is not optimistic. The discovery of various biomarkers, especially microsatellite instability (MSI), programmed cell death-ligand 1 (PD-L1), human epidermal growth factor receptor 2 (HER2), tumor mutational burden (TMB) and Epstein-Barr virus (EBV), has led to the identification of an increasing number of targeted populations and has greatly improved the clinical efficacy of treatments for G/GEJ adenocarcinoma. The ToGA trial added trastuzumab to standard chemotherapy, showed improved survival of patients with HER2-positive advanced G/GEJ adenocarcinoma and brought these patients into a new era of HER2-targeted therapy. Moreover, many HER2-targeted agents have been developed and studied in patients with advanced HER2-positive G/GEJ adenocarcinoma who have demonstrated excellent clinical outcomes. However, many patients experience disease progression with HER2-targeted therapy; hence, new anti-HER2 drugs keep being developed, significantly reducing HER2 resistance. This paper reviews HER2-targeted drugs for advanced metastatic G/GEJ adenocarcinoma, potential resistance mechanisms and future directions.
Breakthroughs in the Systemic Treatment of HER2-Positive Advanced/Metastatic Gastric Cancer: From Singlet Chemotherapy to Triple Combination

Sun Young Rha,Hyun Cheol Chung

DOI: https://doi.org/10.5230/jgc.2023.23.e6

2023-01-01

Journal of Gastric Cancer

Abstract:Gastric cancer is heterogeneous in morphology, biology, genomics, and treatment response. Alterations in human epidermal growth factor receptor 2 (HER2) overexpression, microsatellite instability (MSI) status, programmed death-ligand 1 (PD-L1) levels, and fibroblast growth factor receptor 2 (FGFR2) can be used as biomarkers. Since the combination of fluoropyrimidine/platinum plus trastuzumab that was investigated in the ToGA trial was approved as a standard of care in HER2-positive patients in 2010, no other agents showed efficacy in the first- (HELOISE, LOGiC, JACOB trials) and second- (TyTAN, GATSBY, T-ACT trials) line treatments. Despite the success in treating breast cancer, various anti-HER2 agents, including a monoclonal antibody (pertuzumab), an antibody-drug conjugate (ADC; trastuzumab emtansine [T-DM1]), and a small molecule (lapatinib) failed to translate into clinical benefits until the KEYNOTE-811 (first-line) and DESTINY-Gastri01 (≥second-line) trials were conducted. The incorporation of HER2-directed treatment with immune checkpoint inhibitors in the form of a monoclonal antibody or ADC is now approved as a standard treatment. Despite the promising results of new agents (engineered monoclonal antibodies, bi-specific antibodies, fusion proteins, and small molecules) in the early phase of development, the management of HER2-positive gastric cancer requires further optimization to achieve precision medicine with a chemotherapeutic backbone. Treatment resistance is a complex process that can be overcome using a combination of chemotherapy, targeted agents, and immune checkpoint inhibitors, including novel agents. HER2 status must be reassessed in patients undergoing anti-HER2 treatment with disease progression after the first-line treatment. As a general guideline, patients who need systemic treatment should receive chemotherapy plus targeted agents, anti-angiogenic agents, immune checkpoint inhibitors, or their combinations.

oncology,gastroenterology & hepatology
Retrograde gastric varices in a patient with total cavopulmonary shunt.

A. Furuse,K. Koseni,M. Takeshita,Y. Kotsuka,K. Yagyu,M. Kawauchi

DOI: https://doi.org/10.1016/0003-4975(93)91117-6

1993-06-01

Abstract:
RE: Spontaneous abortion in the UK semiconductor industry.

A. Watterson,M. Silberschmidt,S. Pickvance,R. O’Neill,P. Kirby,J. Brophy,M. Keith,C. Woolfson

American Journal of Industrial Medicine

Abstract:
Her2 Expression in Primary Gastric Cancers and Paired Synchronous Lymph Node and Liver Metastases. A Possible Road to Target Her2 with Radionuclides

Qichun Wei,Jing Xu,Li Shen,Xianhua Fu,Bicheng Zhang,Xiaofeng Zhou,Jorgen Carlsson

DOI: https://doi.org/10.1007/s13277-014-1830-3

2014-01-01

Tumor Biology

Abstract:Resistance has been reported to human epidermal growth factor receptor 2 (HER2)-targeted therapy with the tyrosine kinase inhibitor lapatinib and the antibody trastuzumab in metastatic gastric cancer. An alternative or complement might be to target the extracellular domain of HER2 with therapy-effective radionuclides. The fraction of patients with HER2 expression in primary tumors and major metastatic sites, e.g., lymph nodes and liver, was analyzed to evaluate the potential for such therapy. Samples from primary tumors and lymph node and liver metastases were taken from each patient within a few hours, and to our knowledge, such sampling is unique. The number of analyzed cases was therefore limited, since patients that had received preoperative radiotherapy, chemotherapy, or HER2-targeted therapy were excluded. From a large number of considered patients, only 29 could be included for HER2 analysis. Intracellular mutations were not analyzed since they are assumed to have no or minor effect on the extracellular binding of molecules that deliver radionuclides. HER2 was positive in nearly 52 % of the primary tumors, and these expressed HER2 in corresponding lymph node and liver metastases in 93 and 100 % of the cases, respectively. Similar values for primary tumors and also good concordance with metastases have been indicated in the literature. Thus, relevant radionuclides and targeting molecules for nuclear medicine-based noninvasive, whole-body receptor analysis, dose planning, and therapy can be applied for many patients; see "Discussion" Hopefully, more patients can then be treated with curative instead of palliative intention.
State of the art and upcoming trends in HER2-directed therapies in gastrointestinal malignancies

Jaeyop Lee,Geoffrey Ku

DOI: https://doi.org/10.1097/cco.0000000000001043

2024-05-11

Current Opinion in Oncology

Abstract:This review critically evaluates the evolution and current status of human epidermal growth factor receptor 2 (HER2)-directed therapies in upper gastrointestinal (GI) malignancies, a timely and relevant inquiry given the dynamic shifts in therapeutic strategies over the past decade. Initial enthusiasm following the Trastuzumab for Gastric Cancer (ToGA) study's demonstration of trastuzumab's efficacy, however, encountered hurdles due to subsequent trials showing limited progress, underscoring the necessity for a reevaluation of therapeutic approaches and the exploration of novel agents.

oncology

Bacterial mercury resistance from atoms to ecosystems.

Alisporivir, a cyclosporin derivative that selectively inhibits cyclophilin, for the treatment of HCV infection.

HER2-Directed Therapy in Advanced Gastric and Gastroesophageal Adenocarcinoma: Triumphs and Troubles

Immune checkpoint inhibitors combined with HER-2 targeted therapy in HER-2 positive gastroesophageal cancer

What Happened to Detail and Discussion?

Topical antineoplastic agents in the treatment of mucocutaneous diseases.

From rings to crescents: a novel fabrication technique uncovers the transition details.

Th1 and Th2 cells.

Room-temperature triggered single photon emission from a III-nitride site-controlled nanowire quantum dot.

HER2-Positive Gastric Cancer and Antibody Treatment: State of the Art and Future Developments

KEYNOTE-811: Potential to revise first-line therapy for metastatic human epidermal growth factor receptor 2-positive gastric cancer

Fe-salphen complexes from intracellular pH-triggered degradation of Fe3O4@Salphen-InIII CPPs for selectively killing cancer cells.

Targeting HER2-positive breast cancer: advances and future directions

HER2 + advanced gastric cancer: Current state and opportunities (Review)

[A simple method for the synthesis of phosphatidylcholine with the fatty acid substituted in the 2-position].

HER2-targeted Advanced Metastatic Gastric/gastroesophageal Junction Adenocarcinoma: Treatment Landscape and Future Perspectives.

Breakthroughs in the Systemic Treatment of HER2-Positive Advanced/Metastatic Gastric Cancer: From Singlet Chemotherapy to Triple Combination

Retrograde gastric varices in a patient with total cavopulmonary shunt.

RE: Spontaneous abortion in the UK semiconductor industry.

Her2 Expression in Primary Gastric Cancers and Paired Synchronous Lymph Node and Liver Metastases. A Possible Road to Target Her2 with Radionuclides

State of the art and upcoming trends in HER2-directed therapies in gastrointestinal malignancies